Leeches in Microsurgery – An Evidence-Based Approach

Knobloch, Karsten

doi:10.1007/978-90-481-9295-3_42

Cited by 3 publications

(1 citation statement)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consequently, a large number of peptides and proteins with tremendous clinical applications have been identified and characterized in leech extract, such as antithrombin agents [6,7], antiplatelet compounds [8][9][10], etc. Nowadays, leeches have been introduced as promising tools in microsurgery and reconstructive operations after many reports about better salvage of grafted tissues and amputated digits after leech application [11,12].…”

Section: Introductionmentioning

confidence: 99%

Anticancer Effects of Medical Malaysian Leech Saliva Extract (LSE)

Merzouk¹

2012

Pharm Anal Acta

View full text Add to dashboard Cite

Leech saliva contains biologically active compounds that are mainly proteins & peptides. Small cell lung cancer (SCLC) is a form of cell lung carcinoma. In this study a modified and smooth extraction method of saliva was used without leech scarification. Trying to find out the biological activity of medical Malaysian Leech Saliva Extract as cytotoxic in vitro, the SW 1271 cell line was grown and maintained in Leibovitz ' s L-15 medium supplemented with 10% foetal bovine serum at 37°C in normal atmospheric air. Serial dilutions of LSE were added to the cell line SW 1271 media for testing the cytotoxic activities.Result revealed that the LSE has a cytotoxic activity against small cell lung cancer(SW 1271 cell line) with IC 50 of 119.844 µg/ml compared with IC 50 values of two reference standard drugs Irinotecan (5.81 µg/ml) and Carboplatin(18.754 µg/ml). In a combination regimen, LSE reduced the IC 50 of Carboplatin & Irinotecan by 65% & 11.5% respectively. Carboplatin reduced the IC 50 of LSE by 4.6%, while Irinotecan reduced it by 57%. This results provides a promising novel agent for treatment of small cell lung cancer (SCLC) at least in vitro, more researches are needed.

show abstract

Section: Introductionmentioning

confidence: 99%

Anticancer Effects of Medical Malaysian Leech Saliva Extract (LSE)

Merzouk¹

2012

Pharm Anal Acta

View full text Add to dashboard Cite

show abstract

Tıbbi Sülük Terapisi (Hirudoterapi)

Yaman¹

2019

Journal of Biotechnology and Strategic Health Research

View full text Add to dashboard Cite

Sülükler halkalı omurgasızlar sınıfındadır, kan ile beslenirler ve antik dönemden beri çeşitli hastalıkları tedavi etmek için flebotomide kullanılırlar. Hirudoterapi, tedavi için tıbbi sülüklerin uygulanmasıdır. Sülük tedavisinin terapötik kullanımı köklü bir yöntemdir ve eski Mısır'a, medeniyetin başlangıcına dayanır. 20. yüzyılın sonunda yeni terapi kavramları sülük tedavisinin yerini almıştır. Mikrovasküler cerrahi tekniklerle birlikte son yıllarda tıbbi sülüklerin kullanımında bir "yeniden doğuş" olmuştur. Hirudo medicinalis, sülükler arasında en geniş terapotik kullanıma sahiptir ancak dünya çapında birçok farklı tür test edilmiş ve incelenmiştir. Sülük tedavisi genellikle ağrısız olan bir ilk ısırığı, ardından 5 ila 15 ml kan emmeyi içerir. Başlıca terapötik faydaları sadece ısırma sırasında emilen kandan değil, aynı zamanda çeşitli biyoaktif maddelerden de kaynaklanmaktadır. Sülük tükürüğü; eglin, bdellin, hirudin, hyaluronidaz, calin, destabilas, apiraz, dekorin, hirustatin, triptaz inhibitörleri ve histamin benzeri maddeler, kompleman inhibitörleri, karboksipeptidaz A-inhibitörleri ve asetilkolin gibi çeşitli biyoaktif bileşikler içerir. Bu bileşikler; koagülasyonun inhibisyonundan, analjezik etkiden, kas gevşetici etkiden ve bağışıklık sistemi üzerindeki düzenlemeden sorumludur. Hirudoterapi; kardiyoloji, ortopedi, jinekoloji, oftalmoloji, plastik ve rekonstrüktif cerrahi gibi alanlarda geniş bir terapötik uygulama yelpazesine sahiptir. Bu derleme sülükler hakkında; tarihçesi, genel özellikleri, etki mekanizmaları ve tıbbi bir cihaz olarak uygulanmasını içeren genel bir bakış sunar.

show abstract

Anticoagulants from Hematophagous

Chudzinski-Tavassi¹,

Faria²,

Flores³

2018

Anticoagulant Drugs

View full text Add to dashboard Cite

This chapter will focus on anticoagulant molecules described until now from hematophagous animals. The evolutionary scenario for hematophagous animals is convergent and has resulted on a wide diversity of saliva anticoagulants, substances with platelet antiaggregation action, and also with vase-dilating action. Hematophagous animals such as bloodsuckers (leeches, mosquitoes, and ticks) have developed strategies that specifically target proteinases from the hemostatic system of the animals they feed, thus keeping the blood incoagulable. The saliva of those animals provides a large amount of molecules to modulate the innate immune response of the host and to inhibit blood coagulation in order to facilitate the feeding. Thus, anticoagulants from hematophagous animals represent a very interesting tool for studies ranging from basic research to applications in the therapeutic area, as anticoagulant medication. Several studies have pointed out that anticoagulants from hematophagous can also display non-hemostatic functions as antitumor, bringing new perspectives for the study of these molecules. The comprehension of the multi-faced physiological roles of those new anticoagulants from hematophagous opens new perspectives for therapeutic and biotechnological approaches.

show abstract

Leeches in Microsurgery – An Evidence-Based Approach

Cited by 3 publications

References 44 publications

Anticancer Effects of Medical Malaysian Leech Saliva Extract (LSE)

Anticancer Effects of Medical Malaysian Leech Saliva Extract (LSE)

Tıbbi Sülük Terapisi (Hirudoterapi)

Anticoagulants from Hematophagous

Contact Info

Product

Resources

About